Leadership Change at Tessera Therapeutics
Tessera Therapeutics, a revolutionary company in genetic medicine known for its innovative Gene Writing™ technology, is set for a significant leadership transition. The existing Chief Financial Officer (CFO), Howard Liang, has announced that he will step down from his position at the end of the year. Liang will continue to serve as President until the transition is complete, ensuring a smooth shift in leadership.
Contribution of Howard Liang
The announcement from Tessera's CEO, Michael Severino, M.D., expressed deep gratitude for Howard's five years of dedicated service. His contributions have been pivotal in shaping the company's strategic direction and enhancing its core value. Severino emphasized that Liang's leadership has laid a solid groundwork for Tessera's long-term success. He concluded by wishing Howard well as he embarks on a new journey in his career.
Introducing Kathy Bergsteinsson as New CFO
In light of this change, Tessera is thrilled to welcome Kathy Bergsteinsson as its new Chief Financial Officer. Bergsteinsson is a seasoned executive with over 25 years of experience encompassing management, corporate finance, capital markets, mergers and acquisitions (M&A), and strategic planning. Prior to joining Tessera, she served as CFO at Affini-T Therapeutics, contributing her extensive knowledge and expertise.
Kathy's Impressive Background
Kathy’s career includes a notable 18-year tenure at Morgan Stanley, where she held the position of Managing Director and led Healthcare Equity Capital Markets. Her efforts contributed to over $100 billion in equity financings for clients and approximately $110 billion in strategic M&A transactions. Kathy graduated with a Bachelor of Science degree in industrial engineering from Stanford University and earned her MBA from The Wharton School at the University of Pennsylvania.
A Vision for the Future
Upon her appointment, Kathy expressed enthusiasm for joining Tessera at this critical phase of its growth trajectory. She reiterated her commitment to advancing Tessera’s innovative Gene Writing platform, which promises to transform genetic medicine profoundly. Her deep understanding of the healthcare sector aligns perfectly with the company’s strategic objectives, positioning her as an essential asset for Tessera’s future endeavors.
Commitment to Patients
Kathy articulated her excitement about partnering with the leadership team to bolster Tessera's strategic vision. Her goal is to enhance existing programs and contribute to the development of groundbreaking solutions that could significantly impact patient care. The Gene Writing technology not only aims to correct genetic disorders but also seeks to redefine treatment options for various diseases.
About Tessera Therapeutics
Tessera Therapeutics is at the forefront of pioneering genetic medicine through its Gene Writing™ technology. By enabling precise modifications to the genome, Tessera aims to unlock new therapeutic possibilities. The company’s advanced Gene Writing platform allows for targeted changes at the DNA level, offering the potential to address diseases caused by single-gene errors and modify inherited risk factors for more common conditions. With a proprietary lipid nanoparticle delivery system, Tessera aspires to ensure effective in vivo delivery of RNA to specific cell types, heralding a new era of genetic therapies.
Looking Ahead
Founded in 2018 by Flagship Pioneering, Tessera Therapeutics is committed to transforming human health and sustainability through innovative biotechnology solutions. The leadership transition comes at a time when the company is poised to make significant strides in the field of genetic medicine. Kathy’s appointment is seen as a strategic move to pave the way for future successes and breakthroughs.
Frequently Asked Questions
What is Tessera Therapeutics known for?
Tessera Therapeutics is known for pioneering Gene Writing™ technology, which aims to revolutionize genetic medicine through innovative treatments.
Who is the new CFO of Tessera Therapeutics?
Kathy Bergsteinsson has been appointed as the new Chief Financial Officer of Tessera Therapeutics.
What experience does Kathy Bergsteinsson bring?
Kathy brings over 25 years of experience in corporate finance, capital markets, and strategy, with prior roles including CFO at Affini-T Therapeutics and Managing Director at Morgan Stanley.
When will Howard Liang step down as CFO?
Howard Liang will step down from his role as CFO at the end of the year, while ensuring a smooth transition until then.
What are the future plans for Tessera Therapeutics?
Tessera Therapeutics aims to advance its Gene Writing technology and expand its therapeutic applications, focusing on innovative treatments for diseases.
